Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-DOTA-TATE in Newly Diagnosed and Recurrent Glioblastoma
NCT05109728Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2022
- Primary completion
- Dec 2025
- Modality
- Peptides, Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of lutetium Lu 177 dotatate in glioblastoma (GBM) (2 arms), sponsored by Novartis. Primary endpoint: Dose Limiting Toxicities. Started May 2022; status: active, not recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05109728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05109728.